The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary The neuromuscular disorder spinal muscular atrophy (SMA), the most common inherited killer of infants, is caused by insufficient expression of survival motor neuron (SMN) protein. SMA therapeutics development efforts have focused on identifying strategies to increase SMN expression. We identified a long non-coding RNA (lncRNA) that arises from the antisense strand of SMN, SMN-AS1, which is enriched in neurons and transcriptionally represses SMN expression by recruiting the epigenetic Polycomb repressive complex-2. Targeted degradation of SMN-AS1 with antisense oligonucleotides (ASOs) increases SMN expression in patient-derived cells, cultured neurons, and the mouse central nervous system. SMN-AS1 ASOs delivered together with SMN2 splice-switching oligonucleotides additively increase SMN expression and improve survival of severe SMA mice. This study is the first proof-of-concept that targeting a lncRNA to transcriptionally activate SMN2 can be combined with SMN2 splicing modification to ameliorate SMA and demonstrates the promise of combinatorial ASOs for treatment of neurogenetic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 5×
“…imprinting (i.e., silencing of alleles in a parent-of-origin-dependent manner), X chromosome inactivation, and irreversible silencing of proteincoding genes by trimethylating H3K27 in their promoter regions (Mager et al., 2003; Margueron and Reinberg, 2011; Pinter et al., 2012; Simon et al., 2013).”
InfluentialFaghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., Finch, C. E., St. Laurent III, G., Kenny, P. J., & Wahlestedt, C. (2008) · Nature Medicine · doi:10.1038/nm1784 · Cited by 1,416 · cited 2×
“…have emergedas key regulators of protein-coding gene expression (Faghihi and Wahlestedt, 2009; Lee, 2012) with natural antisense transcripts (NATs), in particular, often affecting expression of their associated proteincoding genes (Carrieri et al., 2012; Faghihi et al., 2008;Mahmoudi et al., 2009).”
BackgroundRNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617 · cited 2×
“Importantly, although penetration of ASOs into the adult CNS is low after systemic delivery (Hua et al., 2008), clinical trials in patients with amyotrophic lateral sclerosis and SMA have indicated that intrathecal administration is tolerated and safe (Chiriboga et al., 2016; Miller et al., 2013).”
Self-citationSMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., et al. (2014) · Science · doi:10.1126/science.1250127 · Cited by 524 · cited 2×
“Splice-switching oligonucleotides (SSOs) and small molecules promote exon 7 inclusion in SMN2 pre-mRNAs and improve disease phenotypes in SMA mice (Hua et al., 2010; Hua et al., 2011; Naryshkin et al., 2014; Palacino et al., 2015).”
BackgroundSelf-citationNg, S., Johnson, R., & Stanton, L. W. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.459 · Cited by 514
Self-citationSMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice
Palacino, J., Swalley, S. E., Song, C., Cheung, A. K., Shu, L., Zhang, X., Van Hoosear, M., Shin, Y., Chin, D. N., Keller, C. G., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1837 · Cited by 432
Ramos, A. D., Andersen, R. E., Liu, S. J., Nowakowski, T. J., Hong, S. J., Gertz, C. C., Salinas, R. D., Zarabi, H., Kriegstein, A. R., & Lim, D. A. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.02.007 · Cited by 359
Cited by
Mercuri, E., Sumner, C. J., Muntoni, F., Darras, B. T., & Finkel, R. S. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00380-8 · Cited by 430
Self-citationAntisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
Schoch, K. M., & Miller, T. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.010 · Cited by 274
“Other ASO targets, such as long non-coding RNA (lncRNA) SMN sequences, have also shown considerable promise inmodulating SMN expression and extending survival inmice (d’Ydewalle et al., 2017).”
Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy
Qian, Y., Shi, L., & Luo, Z. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.612393 · Cited by 261
Wirth, B., Karakaya, M., Kye, M. J., & Mendoza-Ferreira, N. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-102319-103602 · Cited by 255
Metadata
- Authors
- d’Ydewalle, C., Ramos, D. M., Pyles, N. J., Ng, S.-Y., Gorz, M., Pilato, C. M., Ling, K., Kong, L., Ward, A. J., Rubin, L. L., Rigo, F., Bennett, C. F., & Sumner, C. J.
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 93
- Issue
- 1
- Pages
- 66-79
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W2562013491
- Cited by
- 136
- References
- 11
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.